PT  - JOURNAL ARTICLE
AU  - Coelewij, Leda
AU  - Waddington, Kirsty E
AU  - Robinson, George A
AU  - Chocano, Elvira
AU  - McDonnell, Thomas
AU  - Farinha, Filipa
AU  - Peng, Junjie
AU  - Dönnes, Pierre
AU  - Smith, Edward
AU  - Croca, Sara
AU  - Griffin, Maura
AU  - Nicolaides, Andrew
AU  - Rahman, Anisur
AU  - Jury, Elizabeth C
AU  - Pineda-Torra, Ines
TI  - Using serum metabolomics analysis to predict sub-clinical atherosclerosis in patients with SLE
AID  - 10.1101/2020.08.11.20172536
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.11.20172536
4099  - http://medrxiv.org/content/early/2020/08/12/2020.08.11.20172536.short
4100  - http://medrxiv.org/content/early/2020/08/12/2020.08.11.20172536.full
AB  - Background Patients with systemic lupus erythematosus (SLE) have an increased risk of developing cardiovascular disease (CVD) and 30-40% have sub-clinical atherosclerosis on vascular ultrasound scanning. Standard measurements of serum lipids in clinical practice do not predict CVD risk in patients with SLE. We hypothesise that more detailed analysis of lipoprotein taxonomy could identify better predictors of CVD risk in SLE.Methods Eighty patients with SLE and no history of CVD underwent carotid and femoral ultrasound scans; 30 had atherosclerosis plaques (SLE-P) and 50 had no plaques (SLE-NP). Serum samples obtained at the time of the scan were analysed using a lipoprotein-focused metabolomics platform assessing 228 metabolites by nuclear magnetic resonance spectroscopy. Data was analysed using logistic regression and five binary classification models with 10-fold cross validation; decision tree, random forest, support vector machine and lasso (Least Absolute Shrinkage and Selection Operator) logistic regression with and without interactions.Results Univariate logistic regression identified four metabolites associated with the presence of sub-clinical plaque; three subclasses of very low density lipoprotein (VLDL) (percentage of free cholesterol in medium and large VLDL particles and percentage of phospholipids in chylomicrons and extremely large VLDL particles) and Leucine. Together with age, these metabolites were also within the top features identified by the lasso logistic regression (with and without interactions) and random forest machine learning models. Logistic regression with interactions differentiated between SLE-P and SLE-NP with greatest accuracy (0.800). Notably, percentage of free cholesterol in large VLDL particles and age were identified by all models as being important to differentiate between SLE-P and SLE-NP patients.Conclusion Serum metabolites are a promising biomarker for prediction of sub-clinical atherosclerosis development in SLE patients and could provide novel insight into mechanisms of early atherosclerosis development.Competing Interest StatementThe authors have declared no competing interest.Funding StatementLC is supported by UCL & Birkbeck MRC Doctoral Training Programme. GAR was supported by a PhD studentship from Lupus UK and The Rosetrees Trust (M409). KEW was funded by a British Heart Foundation PhD Studentship (FS/13/59/30649). JP is supported by Versus Arthritis grant reference 21226. This work was also supported by NIHR UCLH Biomedical Research Centre grant reference BRC531/III/IPT/101350 (IPT/ECJ).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Combined University College London/University College London Hospitals Research Ethics Committee (Reference 06/Q0505/79).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesMetabolomic data will be made available in an open access repository upon acceptance for publication in a peer reviewed journal